|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, these results confirm that decreased expression of miR-185 might be regarded as a tumor marker for the early diagnosis of OS, by manipulating of its interactive factors with VAMP2, to provide an effective novel therapeutic target for treatment of the OS tumor.
|
30721745 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, we confirmed that miR-185 suppressed the tumor growth of NSCLC A549 cells in vivo.
|
29716672 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we further confirmed that RNCR3 binds to miR-185-5p, which has been identified as a tumor suppressor in some human cancers, including prostate cancer.
|
29887969 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-185 also inhibited tumor growth and suppressed SOX13 in nude mouse xenograft tumors.
|
30210696 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of miR‑185 was associated with tumor size, differentiation and lymphatic metastasis.
|
29257260 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical features revealed a negative correlation between miR‑185‑5p and tumor size, as well as in tumor differentiation and lymph node metastasis in breast cancer.
|
30015912 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-185 is involved in cell growth, motility and survival of Ewing's sarcoma as a tumor suppressor via suppressing PI3K/Akt/mTOR and Wnt/β-catenin pathways and targeting E2F6.
|
30519038 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A tumor formation assay was performed to determine the radiosensitization effect of miR-185 on melanoma cells <i>in vivo</i>.
|
28454417 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of miR-185 had a negative correlation with tumor size, Fuhrman grade, and TNM staging.
|
25700976 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Plasma miR-185 is decreased in patients with esophageal squamous cell carcinoma and might suppress tumor migration and invasion by targeting RAGE.
|
26316588 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we confirmed that the expression of miR-185 was significantly down-regulated in NSCLC tissues and cell lines. miR-185 over-expression caused significant suppression of in vitro cell proliferation, migration and invasion, and in vivo tumor growth.
|
26617940 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, the results of the present study suggested that miR‑185 may be a potential negative modulator of AR‑mediated signaling and may act as a tumor suppressor in prostate cancer cells.
|
25673182 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, these findings indicate that miR‑185 as a tumor suppressor may affect the development of colon cancer cells via inhibition of HIF‑2α signaling, suggesting that miR‑185 may serve as a potential therapeutic target in cancer treatment.
|
25216407 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that miR-185 functions as a tumor suppressor in TNBC development.
|
25319390 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quantitative RT-PCR showed a reduction of miR-185 in human HCC cells compared with primary hepatocytes. miR-185 overexpression in human HCC cells inhibited cell proliferation and invasion in vitro and prevented tumor growth in SCID mice. miR-185 overexpression inhibited DNMT1 3' untranslated region luciferase reporter activity in HCC cells; this effect was abolished when the miR-185 binding site was mutated. miR-185 mimic or overexpression decreased the level of DNMT1 protein in HCC cells.
|
24911372 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR185 closely associated with tumor size, pTNM stage, lymph node, and perneural invasion.
|
24198204 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results manifested that miR-185 could suppress the tumor cell growth and invasive ability (P<0.05).
|
23648054 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that miR-185 could function as a tumor-suppressor gene in CaP by directly targeting AR, and act as a potential therapeutic target for CaP.
|
23417242 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Together, our findings suggest that the altered expression of the tumor suppressor LRRC4 may be an important event that leads to the dysregulation of miR-185 in human gliomas.
|
22834685 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We also discovered two polymorphic nucleotide variations among the more abundant miRNAs miR-181a (T19G) and miR-185 (T16G), but we did not identify nucleotide variations expected for classical tumor suppressor function associated with miRNAs.
|
21586611 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Together, our findings suggest that the altered expression of the novel tumor suppressor miR-185 may be one of the central events that leads to dysregulation of oncogenic protein Six1 in human cancers.
|
20603620 |
2010 |